Clinical Trial Update: CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

This clinical trial update announces a Phase 1 study of CAP-100 for relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma, currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CAP-100

Snippet

Sponsor: Catapult Therapeutics | Conditions: Lymphocytic Leukemia, Chronic, SLL | Phase 1 | Status: RECRUITING